Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
doxorubicin + mitomycin C
- Development stage
- Preclinical
- Lead developer
- Farmitalia
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Doxorubicin + mitomycin C is a combination chemotherapy regimen that has shown synergistic effects against cancer cells, particularly in breast cancer models. The combination has been studied in various formulations, including as co-loaded polymer-lipid hybrid nanoparticles (DMPLN) which can bypass efflux transporter pumps that confer multidrug resistance. However, the combination has shown significant cardiopulmonary toxicity concerns, particularly when mitomycin C is administered frequently (every 3 weeks).
- Other names
- DOX + MMCDMPLN
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on doxorubicin + mitomycin C.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on doxorubicin + mitomycin C.